October 2026 FDA approvals calendar with Hovilpri approved 9 October and Hibsago approved 20 October

October 2026 FDA Approvals: What Pharma Companies Should Know About Comparator Drug Sourcing

New drug approvals bring new treatment options and potential market opportunities. But what do they mean for companies planning their next generic or biosimilar development program? October 2026 had two important FDA approvals. Hovilpri (pritelivir) was approved for difficult-to-treat herpes simplex virus (HSV) infections and Hibsago (bepirovirsen) for chronic hepatitis B. Both drugs introduce new…

Read More

September 2026 FDA drug approvals: 9 new drugs including Zanvastro, Etcamah, Onswik, Juvmo and Emcitate with approval dates

FDA Drug Approvals September 2026: 9 New Drugs, Market Insights & Filing Opportunities

September 2026 brought 9 new FDA drug approvals, spanning rare neurological diseases, oncology, diabetes, diagnostic imaging, and movement disorders. These approvals introduce new treatment options and highlight potential opportunities around market growth, exclusivity timelines, and future filing strategies for pharmaceutical companies. Each new approval also brings potential future requirements for comparator and RLD sourcing, as…

Read More

FDA approved stamp on vial representing August 2026 drug approvals

August 2026 FDA Approvals: 7 New Drugs Creating Future Market Opportunities

The FDA approved 7 new drugs in August 2026. These approvals introduced new treatment approaches across sleep disorders, Alzheimer's disease diagnostics, oncology, rare diseases, autoimmune conditions, and hematology. For pharma companies, each approval can signal future opportunities around market entry, exclusivity timelines, and filing strategies. These approvals may also create future requirements for comparator sourcing,…

Read More

Hand stamping approval on a document, representing FDA drug approvals granted in July 2026

July 2026 FDA Approvals: 6 New Drugs With Billion-Dollar Potential

6 new drugs were approved by the FDA in the month of July. These drugs created new opportunities across oncology, immunology, cardiovascular care, ophthalmology, and CNS therapies. They hint at new market opportunities, exclusivity timelines, and potential filing strategies for the decision-making teams. Each new approval also signals a future comparator & RLD sourcing requirement,…

Read More

Controlled clinical trial with two patient arms receiving comparator and investigational drug while a clinician records outcome data

Understanding Controlled Clinical Trials: Design, Comparators and the Supply Chain Behind the Data

A drug can look brilliant in a single-arm study and fail completely once placed head-to-head against an active control. That gap between apparent effect and real effect is the entire reason controlled clinical trials exist. Most participants improve for reasons that have nothing to do with the investigational product. Disease states fluctuate. Trial participants often…

Read More

Request a Quote

Fill out the form below, and we will be in touch shortly.